Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

The MP0250-CP201 Mirror Study: A Phase 2 Study Update of MP0250 Plus Bortezomib and Dexamethasone in Relapse/Refractory Multiple Myeloma (RRMM) Patients Previously Exposed to Proteasome Inhibitors and Immunomodulatory Drugs

Norbert Grząśko, MD PhD, Stefan Knop, Hartmut Goldschmidt, MD, Marc S Raab, MD PhD, Jan Dürig, Sara Bringhen, Mattia D'Agostino, MD, Barbara Gamberi, Elena Rivolti, MD, Angelo Vacca, MD PhD, Roberto Ria, MD, Artur Jurczyszyn, MD, Jorge Castellano Acosta, MD, Doris Lang, Guy Lemaillet, PhD, Bansod Sudhir, MD, Monika Szarejko, MD

Blood (2019) 134 (Supplement_1): 1899.

https://doi.org/10.1182/blood-2019-129827

Published: 2019

Journal Articles

The Prognostic Impact of t(14;16) in Multiple Myeloma: A Multicenter Retrospective Study of 213 Patients. Is It Time to Revise the Revised ISS?

Blood (2018) 132 (Supplement 1): 4452.

https://doi.org/10.1182/blood-2018-99-115971

Published: 2018

Journal Articles

The Prognostic Impact of t(14;20) in Multiple Myeloma - a Multicenter Retrospective Study of 26 Patients

Artur Jurczyszyn, MD, Sarah Goldman-Mazur, MD, Jorge J. Castillo, MD, Anna Waszczuk-Gajda, Norbert Grząśko, MD PhD, Max Bittrich, MD, Andrew J Yee, MD, Anna Suska, MD, Deepu Madduri, MD, Saurabh Chhabra, MD, Ariel Kleman, MD, Parameswaran Hari, MBBS, MD, Stuart L. Goldberg, MD, Aimee Chappell, Massimo Gentile, David H. Vesole, MD PhD

Blood (2018) 132 (Supplement 1): 5600.

https://doi.org/10.1182/blood-2018-99-115816

Published: 2018

Journal Articles

MP0250 Combined with Bortezomib and Dexamethasone in Multiple Myeloma Patients Previoulsy Exposed to Proteasome Inhibitors and Immunomodulatory Drugs

Stefan Knop, Hartmut Goldschmidt, MD, Marc S Raab, MD PhD, Monika Szarejko, Artur Jurczyszyn, MD, Jan Dürig, Sara Bringhen, Barbara Gamberi, MD, Angelo Vacca, Jorge Castellano Acosta, MD, Guy Lemaillet, PhD, Cedric Cortijo, PhD, Bansod Sudhir, Norbert Grząśko, MDPhD

Blood (2018) 132 (Supplement 1): 1980.

https://doi.org/10.1182/blood-2018-99-112859

Published: 2018

Journal Articles

Efficacy and Safety of Long-Term Ixazomib Maintenance Therapy in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Not Undergoing Transplant: An Integrated Analysis of Four Phase 1/2 Studies

Meletios A. Dimopoulos, Jacob Laubach, MD, Maria Asuncion Echeveste Gutierrez, Norbert Grząśko, Craig C Hofmeister, MDMPH, Jesus F. San Miguel, MD, Shaji K Kumar, MD, Vickie Lu, PhD, Zhaoyang Teng, PhD, Guohui Liu, PhD, Catriona Byrne, RN, Deborah Berg, RN, MSN, Richard Labotka, MD MS, Helgi van de Velde, MD PhD, Paul G Richardson, MD

Blood (2017) 130 (Supplement 1): 902.

https://doi.org/10.1182/blood.V130.Suppl_1.902.902

Published: 2017

Journal Articles

Preemptive Daratumumab Therapy for Minimal Residual Disease Reappearance or Biochemical Relapse in Multiple Myeloma: Rationale and Design of the Polish Myeloma Consortium Predator Study

Krzysztof Jamroziak, Krzysztof Giannopoulos, Tomasz Wrobel, MD PhD, Adam Nowicki, Bartosz Pula, Norbert Grząśko, Justyna Rybka, Paweł J. Robak, MD, Agnieszka Druzd-Sitek, Adam Walter-Croneck, Katarzyna Brzeźniakiewicz-Janus, MDPhD, Jarosław Czyż, Krzysztof Warzocha, Dominik Dytfeld

Blood (2017) 130 (Supplement 1): 5404.

https://doi.org/10.1182/blood.V130.Suppl_1.5404.5404

Published: 2017

Journal Articles

Analysis of the PD-1/PD-L1 Axis Points to Association of Unfavorable Recurrent Mutations with PD-L1 Expression in AML

Malgorzata Zajac, PhD, Joanna Zaleska, Anna Dolnik, PhD, Anna Siwiec, PhD, Olga Jankowska-Lecka, PhD, Radoslaw Mlak, PhD, Marzanna Ciesielka, PhD, Tomasz Gromek, MD PhD, Bozena Sokolowska, MD PhD, Norbert Grzasko, MD PhD, Maria Soroka-Wojtaszko, MD PhD, Aneta Szudy-Szczyrek, MD, Maria Majdan, MD, Marek Hus, MD PhD, Lars Bullinger, MD, Krzysztof Giannopoulos, MD PhD

Blood (2016) 128 (22): 1685.

https://doi.org/10.1182/blood.V128.22.1685.1685

Published: 2016

Journal Articles

Phase 2 Study of the All-Oral Combination of Ixazomib Plus Cyclophosphamide and Low-Dose Dexamethasone (ICd) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Shaji Kumar, MD, Norbert Grzasko, MD PhD, Sosana Delimpasi, MD, Wieslaw W Jędrzejczak, MD, Sebastian Grosicki, MD PhD, Marie-Christine Kyrtsonis, MD PhD, Andrew Spencer, Neeraj Gupta, PhD, Zhaoyang Teng, PhD, Catriona Byrne, RN, Richard Labotka, MD MS, Meletios A Dimopoulos

Blood (2016) 128 (22): 3327.

https://doi.org/10.1182/blood.V128.22.3327.3327

Published: 2016

Journal Articles

Clinical and Biological Role of Accumulation of the NPM-1 Splice Variant R2 in AML, MDS and sAML

Grazyna Stasiak, PhD, Malgorzata Zajac, PhD, Joanna Zaleska, Michal Kielbus, PhD, Jakub Czapinski, Andrzej Stepulak, MD PhD, Olga Jankowska-Lecka, PhD, Tomasz Gromek, MD PhD, Norbert Grzasko, MD PhD, Maria Soroka-Wojtaszko, MD PhD, Aneta Szudy-Szczyrek, MD, Bozena Sokolowska, MD PhD, Marek Hus, MD PhD, Lars Bullinger, MD PhD, Krzysztof Giannopoulos, MD PhD

Blood (2016) 128 (22): 2878.

https://doi.org/10.1182/blood.V128.22.2878.2878

Published: 2016

Journal Articles

Ixazomib, an Investigational Oral Proteasome Inhibitor (PI), in Combination with Lenalidomide and Dexamethasone (IRd), Significantly Extends Progression-Free Survival (PFS) for Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): The Phase 3 Tourmaline-MM1 Study (NCT01564537)

Blood (2015) 126 (23): 727.

https://doi.org/10.1182/blood.V126.23.727.727

Published: 2015

Journal Articles

Randomized Phase 2 Study of the All-Oral Combination of Investigational Proteasome Inhibitor (PI) Ixazomib Plus Cyclophosphamide and Low-Dose Dexamethasone (ICd) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Transplant-Ineligible (NCT02046070)

Meletios A. Dimopoulos, Sebastian Grosicki, MD PhD, Wieslaw W Jedrzejczak, MDPhD, Hareth Nahi, Astrid Gruber, MD PhD, Markus Hansson, Catriona Byrne, RN, Richard Labotka, MD MS, Ai-Min Hui, MD PhD, Zhaoyang Teng, PhD, Norbert Grzasko, MD PhD

Blood (2015) 126 (23): 26.

https://doi.org/10.1182/blood.V126.23.26.26

Published: 2015

Journal Articles

Cereblon ( CRBN) Gene Polymorphisms Predict Clinical Response and Progression-Free Survival in Multiple Myeloma Patients Treated with Lenalidomide: A Pharmacogenetic Study of Immense Consortium

Blood (2014) 124 (21): 3628.

https://doi.org/10.1182/blood.V124.21.3628.3628

Published: 2014

Journal Articles

Impact of 1q21 Amplification Alone and in Combination with Other Genetic Abnormalities on Outcome in Multiple Myeloma Patients Treated with Thalidomide-Based Regimens

Norbert Grzasko, MD, PhD, Marek Hus, MD, PhD, Marta Morawska, MD, PhD, Roman Hajek, MD, PhD, Anna Dmoszynska

Blood (2011) 118 (21): 2874.

https://doi.org/10.1182/blood.V118.21.2874.2874

Published: 2011

Journal Articles

Efficacy and Safety of Biosimilar G-CSF and Originator G-CSF for Haematopoietic Stem Cell Mobilisation: A Randomised Comparison

Anna Dmoszynska, Joanna Manko, MD, Adam Walter Croneck, MD, Norbert Grzasko, MD, Piotr Klimek, MD, Aleksandra Nowaczynska, MD, Magdalena Gorska-Kosicka, MD

Blood (2011) 118 (21): 4392.

https://doi.org/10.1182/blood.V118.21.4392.4392

Published: 2011

Journal Articles

Lovastatin and Thalidomide Have an Synergic Effect on the Rate of Multiple Myeloma Cell Apoptosis in Short Term Cell Cultures.

Monika Podhorecka, MD, PhD, Piotr Klimek, MSc, Norbert Grzasko, MD, Anna Dmoszynska, MD, PhD

Blood (2005) 106 (11): 5121.

https://doi.org/10.1182/blood.V106.11.5121.5121

Published: 2005

Journal Articles

Lovastatin as Salvage Immunomodulatory Therapy in Patients with Refractory and Relapsed Multipla Myeloma.

Marek Hus, MD, PhD, Norbert Grzasko, MD, Dariusz Jawniak, MD, PhD, Marta Szostek, PhD, Anna Dmoszynska, MD, PhD

Blood (2005) 106 (11): 1567.

https://doi.org/10.1182/blood.V106.11.1567.1567

Published: 2005

Journal Articles

Stimulation of Erythropoiesis by Thalidomide in Multiple Myeloma Patients: Its Influence on FasL, TRAIL and Their Receptors on Erythroblasts and Plasma Cells.

Norbert Grzasko, MD, Marek Hus, MD, PhD, Maria Soroka-Wojtaszko, MD, PhD, Piotr Klimek, MSc, Aneta Goracy, MSc, Anna Dmoszynska, MD, PhD

Blood (2005) 106 (11): 5120.

https://doi.org/10.1182/blood.V106.11.5120.5120

Published: 2005

NARROW

The MP0250-CP201 Mirror Study: A Phase 2 Study Update of MP0250 Plus Bortezomib and Dexamethasone in Relapse/Refractory Multiple Myeloma (RRMM) Patients Previously Exposed to Proteasome Inhibitors and Immunomodulatory Drugs

The Prognostic Impact of t(14;16) in Multiple Myeloma: A Multicenter Retrospective Study of 213 Patients. Is It Time to Revise the Revised ISS?

The Prognostic Impact of t(14;20) in Multiple Myeloma - a Multicenter Retrospective Study of 26 Patients

MP0250 Combined with Bortezomib and Dexamethasone in Multiple Myeloma Patients Previoulsy Exposed to Proteasome Inhibitors and Immunomodulatory Drugs

Efficacy and Safety of Long-Term Ixazomib Maintenance Therapy in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Not Undergoing Transplant: An Integrated Analysis of Four Phase 1/2 Studies

Preemptive Daratumumab Therapy for Minimal Residual Disease Reappearance or Biochemical Relapse in Multiple Myeloma: Rationale and Design of the Polish Myeloma Consortium Predator Study

Analysis of the PD-1/PD-L1 Axis Points to Association of Unfavorable Recurrent Mutations with PD-L1 Expression in AML

Phase 2 Study of the All-Oral Combination of Ixazomib Plus Cyclophosphamide and Low-Dose Dexamethasone (ICd) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Clinical and Biological Role of Accumulation of the NPM-1 Splice Variant R2 in AML, MDS and sAML

Ixazomib, an Investigational Oral Proteasome Inhibitor (PI), in Combination with Lenalidomide and Dexamethasone (IRd), Significantly Extends Progression-Free Survival (PFS) for Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): The Phase 3 Tourmaline-MM1 Study (NCT01564537)

Randomized Phase 2 Study of the All-Oral Combination of Investigational Proteasome Inhibitor (PI) Ixazomib Plus Cyclophosphamide and Low-Dose Dexamethasone (ICd) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Transplant-Ineligible (NCT02046070)

Cereblon ( CRBN) Gene Polymorphisms Predict Clinical Response and Progression-Free Survival in Multiple Myeloma Patients Treated with Lenalidomide: A Pharmacogenetic Study of Immense Consortium

Impact of 1q21 Amplification Alone and in Combination with Other Genetic Abnormalities on Outcome in Multiple Myeloma Patients Treated with Thalidomide-Based Regimens

Efficacy and Safety of Biosimilar G-CSF and Originator G-CSF for Haematopoietic Stem Cell Mobilisation: A Randomised Comparison

Lovastatin and Thalidomide Have an Synergic Effect on the Rate of Multiple Myeloma Cell Apoptosis in Short Term Cell Cultures.

Lovastatin as Salvage Immunomodulatory Therapy in Patients with Refractory and Relapsed Multipla Myeloma.

Stimulation of Erythropoiesis by Thalidomide in Multiple Myeloma Patients: Its Influence on FasL, TRAIL and Their Receptors on Erythroblasts and Plasma Cells.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only